Liste der im Rahmen der Projekte entstandenen Originalarbeiten

1.   Rawling, J. S., Gatzka, M., Thomas, P. G., and J.N. Ihle. 2011. Chromatin condensation via the condensin II complex is required for peripheral T cell quiescence. EMBO Journal, 30(2):263-276. IF 9,21

2.   Singh, K.*, Gatzka, M.*, Peters, T., Borkner, L., Wang, H., Sindrilaru, A., and K. Scharffetter-Kochanek. 2013. Reduced CD18 levels drive Treg conversion into Th17 cells in the CD18hypo PL/J mouse model of psoriasis. Journal of Immunology, 190(6):2544-2553. * contributed equally IF 5,52

3.    Gatzka, M., Hainzl, A., Peters, T., Singh, K., Tasdogan, A., Wlaschek, M., and K. Scharffetter-Kochanek. 2013. Reduction of CD18 promotes expansion of inflammatory gd T  cells collaborating with CD4+ T cells in murine chronic psoriasiform dermatitis. Journal of Immunology, 191(11):5477-5488. IF 5,52

4. Gatzka, M., Tasdogan, A., Hainzl, A., Allies, G., Maity, P., Wilms, C., Wlaschek, M., and K. Scharffetter-Kochanek. 2014. Histone deubiquitinase 2A-DUB/Mysm1 regulates critical checkpoints of early T cell development and lymphopoiesis via p53-dependent and -independent mechanisms. Cell Death Differ. 2015 Sep; 22(9): 1451-1462. Published online 2015 Jan 23. doi:10.1038/cdd.2014.231

5.   Schlenk RF, Kayser S, Bullinger L, Kobbe G, Casper J, Ringhoffer M, Held G,Brossart P, Lübbert M, Salih HR, Kindler T, Horst HA, Wulf G, Nachbaur D, Götze K, Lamparter A, Paschka P, Gaidzik VI, Teleanu V, Späth D, Benner A, Krauter J, Ganser A, Döhner H, Döhner K. Differential impact of allelic ratio and insertionsite in FLT3-ITD positive AML with respect to allogeneic hematopoietic stem cell transplantation. Blood. 2014 Sep 30. pii: blood-2014-05-578070. [Epub ahead of print] PubMed PMID: 25270908. IF 9,775

6.   Kayser S, Zucknick M, Döhner K, Krauter J, Köhne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, Rummel M, Germing U, Götze K, Nachbaur D, Schlegelberger B, Göhring G, Späth D, Morlok C, Teleanu V, Ganser A, Döhner H, Schlenk RF; German-Austrian AML Study Group. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatmentstrategies. Blood. 2012 Jan 12;119(2):551-8. doi: 10.1182/blood-2011-07-367508. Epub 2011 Nov 16. PubMed PMID: 22096250. IF 9,775

7.   Weissinger SE, Lennerz JK. Comparison of MelanA/MART-1 and HMB45 Labeling in Desmoplastic Melanoma. Mod Pathol 2014 Oct;27(10):1421-3.  IF 5,25

8.   Nagel PD, Stenzinger A, Feld FM, Hermann MD, Brüderlein S, Barth TF, Marienfeld R, Endris V, Weichert W, Debatin KM, Westhoff MA, Lessel D, Möller P, Lennerz JK.  KIT mutations in primary mediastinal B-cell lymphoma. Blood Cancer J 2014 Aug;22(4):epub ahead of print IF 2,88

9.   Stenzinger A, Endris V, Pfarr N, Andrulis M, Jöhrens K, Klauschen F, Siebolts U, Wolf T, Koch PS, Schulz M, Hartschuh W, Goerdt S, Lennerz JK, Wickenhauser C, Klapper W, Anagnostopoulos I, Weichert W. Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm. Oncotarget  2014 Aug;5(15):6404-13 IF 6.64

10. Liedert A, Röntgen V, Schinke T, Benisch P, Ebert R, Jakob F, Klein-Hitpass L, Lennerz JK, Amling M, Ignatius A. Osteoblast-specific Krm2 overexpression and Lrp5 deficiency have different effects on fracture healing in mice. PLoS One 2014 Jul;9(7):e103250 IF 3,53

11. Eberhardt M, Dux M, Namer B, Miljkovic J, Cordasic N, Will C, Kichko TI, de la Roche J, Fischer M, Suárez SA, Bikiel D, Dorsch K, Leffler A, Babes A, Lampert A, Lennerz JK, Jacobi J, Martí MA, Doctorovich F, Högestätt ED, Zygmunt PM, Ivanovic-Burmazovic I, Messlinger K, Reeh P, Filipovic MR. H2S and NO cooperatively regulate vascular tone by activating a neuroendocrine HNO-TRPA1-CGRP signalling pathway. Nature Commun 2014 Jul;5:4381 IF 10,742

12. Bubolz AM, Weissinger SE, Stenzinger A, Arndt A, Steinestel K, Brüderlein S, Cario H, Lubatschofski A, , Welke C, Anagnostopoulos I, Barth TF, Beer AJ, Möller P, Gottstein M, Viardot A, Lennerz JK. Potential clinical implications of BRAF mutations in histiocytic proliferations. Oncotarget 2014; Jun5(12):4060-70 IF 6,63

13. Steinestel K, Lennerz JK, Eder S, Kraft K, Arndt A. Invasion pattern and histologic features of tumor aggressiveness correlate with MMR protein expression, but are independent of activating KRAS and BRAF mutations in CRC. Virchows Arch. 2014 Aug;465(2):155-63 IF 5,40

14. Feld FM, Lennerz JK.  Jaundice in resected pancreatic cancer patients. HPB (Oxford). 2014 Feb;16(2):195 IF 1,93

15. Nagel PD, Feld FM, Weissinger SE, Stenzinger A, Möller P, Lennerz JK. Absence of BRAF and KRAS hotspot mutations in primary mediastinal B-cell lymphoma. Leuk Lymphoma. 2014 Feb 4. IF 2,30

16.  Herrmann MD, Lennerz JK, Bullinger L, Bartholomae S, Holzmann K, Westhoff MA, Corbacioglu S, Debatin KM. Transitory dasatinib-resistant states in KIT(mut) t(8;21) acute myeloid leukemia cells correlate with altered KIT expression Exp Hematol. 2014 Feb;42(2):90-100 IF 2,93

17.  Weissinger SE, Keil P, Silvers DN, Klaus BM, Möller P, Horst BA, Lennerz JK.  A diagnostic algorithm to distinguish desmoplastic from spindle cell melanoma. Mod Pathol. 2013 Sep 20. IF 2,95

18. Seiler K, Nusser JI, Lennerz JK, Neuhuber WL, Messlinger K. Changes in calcitonin gene-related peptide (CGRP) receptor component and nitric oxide receptor (sGC) immunoreactivity in rat trigeminal ganglion following glyceroltrinitrate pretreatment.  J Headache Pain. 2013 Sep 3;14(1):74 IF 2,78

19. Kichko TI, Lennerz J, Eberhardt M, Babes RM, Neuhuber W, Kobal G, Reeh PW.  Bimodal concentration-response of nicotine involves the nicotinic acetylcholine receptor, transient receptor potential vanilloid type 1, and transient receptor potential ankyrin 1 channels in mouse trachea and sensory neurons.J Pharmacol Exp Ther. 2013 Nov;347(2):529-39 IF 3,89

20. Lennerz JK, Lauwers GY. Amelanotic adenoma. Int J Surg Pathol. 2013 Oct;21(5):504-5. IF 0,75

21. Ritz O, Rommel K, Dorsch K, Kelsch E, Melzner J, Buck M, Leroy K, Papadopoulou V, Wagner S, Marienfeld R, Brüderlein S, Lennerz JK, Möller P.  STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL). Oncotarget. 2013 Jul;4(7):1093-102. IF 6,63

22.  Geahlen JH, Lapid C, Thorell K, Nikolskiy I, Huh WJ, Oates EL, Lennerz JK, Tian X, Weis VG, Khurana SS, Lundin SB, Templeton AR, Mills JC. Evolution of the human gastrokine locus and confounding factors regarding the pseudogenicity of GKN3. Physiol Genomics. 2013 Aug 1;45(15):667-83. IF 3,93

23. Schif B, Lennerz JK, Kohler CW, Bentink S, Kreuz M, Melzner I, Ritz O, Trümper L, Loeffler M, Spang R, Möller P.  SOCS1 mutation subtypes predict divergent outcomes in diffuse large B-Cell lymphoma (DLBCL) patients. Oncotarget 2013 Jan;4(1):35-47. IF 6,63

24. Mitra D, Luo X, Morgan A, Wang J, Hoang MP, Lo J, Guerrero CR, Lennerz JK, Mihm MC, Wargo JA, Robinson KC, Devi SP, Vanover JC, D'Orazio JA, McMahon M, Bosenberg MW, Haigis KM, Haber DA, Wang Y, Fisher DE. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature. 2012 Nov 15;491(7424):449-53. IF 38,59

25.  Fujita H, Lennerz JK, Chung DC, Patel D, Deshpande V, Yoon SS, Lauwers GY.  Endoscopic surveillance of patients with hereditary diffuse gastric cancer: biopsy recommendations after topographic distribution of cancer foci in a series of 10 CDH1-mutated gastrectomies.  Am J Surg Pathol. 2012 Nov;36(11):1709-17 IF 4,86

26. Meyer AS, Dallenbach FE, Lienert G, Möller P, Lennerz JK.  Application of digital pathology tools. An unusual case of non-Hodgkin lymphoma. Pathologe. 2012 Nov;33 Suppl 2:200-4 IF 0,62

27. Messlinger K, Lennerz JK, Eberhardt M, Fischer MJ. CGRP and NO in the trigeminal system: mechanisms and role in headache generation. Headache. 2012 Oct;52(9):1411-27. doi: IF 2,93

28. Karaosmanoglu AD, Blake MA, Lennerz JK. Abundant macroscopic fat in intra-abdominal lymph nodes involved in the course of a patient with chronic lymphocytic leukaemia: presentation of imaging findings with biopsy correlation. Br J Radiol. 2012 Apr;85(1012):e91-3. IF 2,11

29. Lennerz JK, Klaus BM, Marienfeld RB, Möller P.  Pyrosequencing of BRAF V600E in routine samples of hairy cell leukaemia identifies CD5+ variant hairy cell leukaemia that lacks V600E.  Br J Haematol. 2012;157(2):267-9 IF 4,94

30. http://www.ncbi.nlm.nih.gov/pubmed/?term=Schirmer%20M%5Bauth%5DM Schirmer,1 L Trentin,1,3 M Queudeville,1,4 F Seyfried,1 S Demir,1 E Tausch,2 S Stilgenbauer,2 S M Eckhoff,1 L H Meyer,1,5,* and K-M Debatin1,5. Intrinsic and chemo-sensitizing activity of SMAC-mimetics on high-risk childhood acute lymphoblastic leukemia ALL 2014, Cell Death Dis. 2016 Jan; 7(1): e2052. Published online 2016 Jan 14. doi: 10.1038/cddis.2015.382

 

31. Queudeville M, Seyfried F, Schirmer M, Eckhoff SM, Debatin KM, Meyer LH Rapid engraftment of human ALL in NOD/SCID mice involves deficient apoptosis signalling Cell Death Dis. 2012 Aug 9;3:e364 IF 5,177

32. Löder S, Schirmer M, Bertrand M, Vandenabeele P, Jeremias I, Debatin K-M, Fulda SRIP1 is required for IAP inhibitor-mediated sensitization of acute leukemia cells to chemotherapy-induced apoptosis Leukemia. 2012 May;26(5):1020-9 IF 9,379

33. Schnaiter A, Paschka P, Rossi M, et al. NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H. Blood. 2013 15;122:1266-70.  IF 9,775

34. Dreger P, Schnaiter A, Zenz T, et al. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood. 2013 18;121:3284-8.

35. Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Döhner K, Bühler A, Böttcher S, Ritgen M, Kneba M, Winkler D, Tausch E, Hoth P, Edelmann J, Mertens D, Bullinger L, Bergmann M, Kless S, Mack S, Jäger U, Patten N, Wu L, Wenger MK, Fingerle-Rowson G, Lichter P, Cazzola M, Wendtner CM, Fink AM, Fischer K, Busch R, Hallek M, Döhner H. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014 May 22;123(21):3247-54 IF 9,775

36. Kühn MW, Bullinger L, Gröschel S, Krönke J, Edelmann J, Rücker FG, Eiwen K, Paschka P, Gaidzik VI, Holzmann K, Schlenk RF, Döhner H, Döhner K. Genome-wide genotyping of acute myeloid leukemia with translocation t(9;11)(p22;q23) reveals novel recurrent genomic alterations. Haematologica 2014 Aug;99(8):e133-5. IF 5,868

37. Krönke J, Fink E, et al. Lenalidomide Induces Ubiquitination and Degradation of casein kinase 1A1 in del(5q) MDS, Nature. 2015 Jul 9;523(7559):183-8. doi: 10.1038/nature14610. Epub 2015 Jul 1.

38. Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C, Fabarius A, Proetel U, Schnittger S, Haferlach C, Krause SW, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Müller MC; SAKK and the German CML Study Group. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica. 2014 Sep;99(9):1441-7. doi: 10.3324/haematol.2013.096537. Epub 2014 May16. PubMed PMID: 24837466. IF 5,868

39. Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C, Erben P, Fabarius A, Proetel U, Schnittger S, Krause SW, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Müller MC; SAKK and the German CML Study Group. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia. 2014 Oct;28(10):1988-92. doi: 10.1038/leu.2014.153. Epub 2014 May 6. PubMed PMID: 24798484. IF 9,379

40. Hehlmann R, Müller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, Proetel U, Pletsch N, Pfirrmann M, Haferlach C, Schnittger S, Einsele H, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Ehninger G, Heim D, Heimpel H, Nerl C, Krause SW, Hossfeld DK, Kolb HJ, Hasford J, Saußele S, Hochhaus A. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol. 2014 Feb 10;32(5):415-23. doi: 10.1200/JCO.2013.49.9020. Epub 2013 Dec 2. PubMed PMID: 24297946. IF 17,879

41. Baliakas P, Hadzidimitriou A, Sutton LA, Rossi D, Minga E, Villamor N, Larrayoz M, Kminkova J, Agathangelidis A, Davis Z, Tausch E, Stalika E, Kantorova B, Mansouri L, Scarfò L, Cortese D, Navrkalova V, Rose-Zerilli MJ, Smedby KE, Juliusson G, Anagnostopoulos A, Makris AM, Navarro A, Delgado J, Oscier D, Belessi C, Stilgenbauer S, Ghia P, Pospisilova S, Gaidano G, Campo E, Strefford JC, Stamatopoulos K, Rosenquist R. Novel Gene Mutations In Chronic Lymphocytic Leukemia: Prevalence And Clinical Implications In A Series Of 3185 Cases - Initial Results From The European Research Initiative On CLL (ERIC) Leukemia 2014 Jun 19. doi: 10138/leu.2014.196 [Epub ahead of print] IF 9,379

42.SPREDs (Sprouty related proteins with EVH1 domain) promote self-renewal and inhibit mesodermal differentiation in murine embryonic stem cells.
Mühl B*, Hägele J*, Tasdogan A*, Loula P, Schuh K, Bundschu K.
Dev Dyn. 2015 Apr;244(4):591-606. doi: 10.1002/dvdy.24261. Epub 2015 Mar 13.

43.Glucocorticoids limit acute lung inflammation in concert with inflammatory stimuli by induction of SphK1.
Vettorazzi S, Bode C, Dejager L, Frappart L, Shelest E, Klaßen C, Tasdogan A, Reichardt HM, Libert C, Schneider M, Weih F, Henriette Uhlenhaut N, David JP, Gräler M, Kleiman A, Tuckermann JP.
Nat Commun. 2015 Jul 17;6:7796. doi: 10.1038/ncomms8796

44.Müller M1, Hermann PC1, Liebau S2, Weidgang C3, Seufferlein T1, Kleger A4, Perkhofer L1. The role of pluripotency factors to drive stemness in gastrointestinal cancer. Stem Cell Res. 2016 Mar;16(2):349-57. doi: 10.1016/j.scr.2016.02.005. Epub 2016 Feb 3.

Liste der im Rahmen der Projekte entstandenen Übersichtsarbeiten

1. Geiger H, Denkinger M, Schirmbeck R. Hematopoietic stem cell aging. Curr Opin Immunol. 2014 Aug;29:86-92. doi: 10.1016/j.coi.2014.05.002. Epub 2014 Jun 3. IF 8,2

2. Gatzka M. 2012. The T-side of Mysm1. Immunity, commentary.

3. Kayser S and Levis MJ. FLT3 Tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations. Leuk Lymphoma. 2014, 55(2):243-55 IF 2,605

4. Krönke J. Mechanism of Lenalidomide Activity in Multiple Myeloma. Invited oral presentation at the Annual Meeting of the American Hematology Association (ASH), San Francisco 2014 

5. Schnaiter, A., Stilgenbauer S. Aktuelle Therapieoptionen bei der chronischen lymphatischen Leukämie. Journal Onkologie 2012;12(2):97-105.

6. Schnaiter, A., Stilgenbauer, S. Novel targeted strategies for refractory chronic lymphocytic leukaemia. Ther Adv Hematol. 2011;2(4):249-265.

7. Schnaiter, A., Mertens D., Stilgenbauer, S. Genetics of Chronic Lymphocytic Leukemia. Clin Lab Med. 2011;31(4):649-58 IF 1,35

8. Tausch E, Mertens D, Stilgenbauer S. Advances in treating chronic lymphocytic leukemia. F1000Prime Rep. 2014 Aug 1; IF 6,65